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ABSTRACT
Epidemiological studies have identified that type 2 diabetes mellitus (DM2) is
a significant risk factor for carcinogenesis and cancer death, including breast cancer.
Our previous finding in patients showed that anti-insulin resistance treatments are
associated with improved HER2+ breast cancer survival of diabetic women. However,
there were no transgenic mouse models to study the correlation and explain the
detailed mechanism. We generated a mouse model of HER2+ breast cancer with DM2
by crossing leptin receptor point mutation (Lepr db/+) and MMTV-ErbB2 (neu) mice.
The MMTV-ErbB2/Lepr db/db mice had a poor survival rate compared with MMTVErbB2/Lepr +/+ mice, and the log rank test of the Kaplan-Meier analysis showed that
they were significantly different (P = 0.0004). In addition, we evaluated the impact of
different anti-diabetic medications on cancer-specific survival. MMTV-ErbB2/Lepr
db/db

mice administrated with metformin or rosiglitazone showed improved overall

survival, cumulative tumor incidence, and reduced tumor progression. Anti-insulin
resistance treatments can also reverse the Warburg effect by reducing lactate/pyruvate
ratio through 13C-pyruvate imaging. Cell lines isolated from MMTV-ErbB2/Lepr db/db
mice also showed reduced levels of both oxygen consumption and lactate production
upon metformin treatment. Metformin treatment not only inhibited proliferation and
vi

induced apoptosis in Human HER2+ breast cancer cell lines, but also repressed cMYC mRNA expression, increased proteasome-dependent degradation, and reduced
the downstream key glycolysis enzyme PKM2. Moreover, anti-insulin resistance
treatments dramatically change the microenvironment by reducing serum insulin
levels and this systematic effect attenuated the mTOR/AKT signaling pathway in
tumor samples from MMTV-ErbB2/Lepr db/db mice. Anti-insulin resistance treatments
also affected adipokine expression profiles and may reveal potential targets for
further research. In conclusion, our results indicate the therapeutic effect of antiinsulin resistance treatments on breast cancer metabolism and this animal model also
shed the light on the clinical implications of anti-insulin resistance treatments on
HER2+ breast cancer patients accompanied with the DM2 condition.
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CHAPTER 1. INTRODUCTION

1.1 General background of diabetes mellitus
Diabetes mellitus, or simply diabetes, is a complex metabolic disease
characterized by chronic hyperglycemia and becoming one of the most
important health issues in the United States. According to the Centers for
Disease Control and Prevention (CDC), diabetes affects 25.8 million
Americans which are 8.3% of the U.S. population in 2011. Based on the
percentage of prediabetes patients (35% of U.S. adults aged 20 years old or
older and 50% of adults aged 65 years or older) in 2005-2008, the estimated
number of pre-diabetic American adults ages 20 years or older is about 79
million. It is predicted that one of three man and nearly 2 of 5 women who
born in the U.S. after 200 will have lifetime risk of developing diabetes
(Centers for Disease Control and Prevention. National Center for Chronic
Disease Prevention and Health Promotion. Diabetes at A Glance. Atlanta,
2011; Narayan et al., 2003). The chronic hyperglycemia increases the risk of
long-term complications of vascular diseases including kidney failure,
nontraumatic lower-limb amputations, blindness, hypertension, heart disease,
stroke, and nervous system diseases in the United States.
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1.1.a Categorization of diabetes mellitus
The high levels of blood glucose of diabetes are results from defects in insulin
insulin production, insulin action, or both. Diabetes can be categorized into four
four major types based on American Diabetes Association (2011):

Type I diabetes: This type of diabetes is primarily caused by autoimmune
destruction of β-cells in the pancreas islet. The insulin production from the β-cells in
the pancreas is not sufficient for glucose storage, therefore hyperglycemia. The cause
of this diabetes is partly genetic predispositions, and is also related to environment.
At the end stage, there is little or no insulin secretion from the β-cells and insulin is
required for patient survival. This type of patients is also at higher risk to develop
other autoimmune diseases.

Type II diabetes: Among all patients with diabetes, more than 90% diabetic
patients are having diabetes mellitus type 2 (DM2), which is characterized by insulin
resistance, and the majority of the DM2 patients are overweight and a sedentary life
style (Giovannucci et al., 2010). This form of diabetes is previously defined as
insulin-independent diabetes with an insulin resistance phenotype. The cause of this
type of diabetes is more related with life style and Western diet.

Other specific types of diabetes: There are also other types of diabetes that
were caused by other reasons, e.g. genetic mutations in β-cell function, insulin action,
cystic fibrosis, and drug/chemical-induced diabetes as shown in Table 1.
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Gestational diabetes mellitus: This form of diabetes is carbohydrate
intolerance resulting in hyperglycemia during pregnancy. Women who
develop gestational diabetes will have high risk to develop DM2.
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Table 1—Etiologic classification of diabetes mellitus
(adapted from American Diabetes Association, Diabetes Care 2011, 34(S1): S62-S69)
I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency)
A. Immune mediated
B. Idiopathic
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin
deficiency to a predominantly secretory defect with insulin resistance)
III. Other specific types
E. Drug or chemical induced
A. Genetic defects of β-cell function
1. N-3-pyridylmethyl-N’-p1. Chromosome 12, HNF-1α (MODY3)
nitrophenylurea
2. Chromosome 7, glucokinase (MODY2)
2. Pentamidine
3. Chromosome 20, HNF-4α (MODY1)
3. Nicotinic acid
4. Chromosome 13, insulin promoter factor-1
4. Glucocorticoids
(IPF-1; MODY4)
5. Diazoxide
5. Chromosome 17, HNF-1β (MODY5)
6. β-adrenergic agonists
6. Chromosome 2, NeuroD1 (MODY6)
7. Thiazides
7. Mitochondrial DNA
8. Phenytoin
9. γ-Interferon
B. Genetic defects in insulin action
1. Type A insulin resistance
F. Infections
2. Leprechaunism
1. Congenital rubella
3. Rabson-Mendenhall syndrome
2. Cytomegalovirus
4. Lipoatrophic diabetes
G. Uncommon forms of immuneC. Diseases of the exocrine pancreas
mediated diabetes
1. Pancreatitis
1. “Stiff-man” syndrome
2. Trauma/pancreatectomy
2. Anti-insulin receptor antibodies
3. Neoplasia
4. Cystic fibrosis
H. Other genetic syndromes
5. Hemochromatosis
sometimes associated with diabetes
6. Fibrocalculous pancreatopathy
1. Down syndrome
2. Klinefelter syndrome
D. Endocrinopathies
3. Turner syndrome
1. Acromegaly
4. Wolfram syndrome
2. Cushing’s syndrome
5. Friedreich ataxia
3. Glucagonoma
6. Huntington chorea
4. Pheochromocytoma
7. Laurence-Moon-Biedl
5. Hyperthyroidism
syndrome
6. Somatostatinoma
8. Myotonic dystrophy
7. Aldosteronoma
9. Porphyria
10. Prader-Willi syndrome
IV. Gestational diabetes mellitus
Patients with any form of diabetes may require insulin treatment at some stage of their
disease. Such use of insulin does not, of itself, classify the patient.
4

1.2 General background of breast cancer
Although breast cancer mortality is decreasing due to increased
awareness, improved detection/screening methods, and novel treatments, it is
remaining the most frequent diagnosed cancer and the second leading cause of
cancer death in women. During 2014, there are estimated 232,670 new cases
of invasive breast cancer and an estimated 40,000 of breast cancer death for
women in the United States. The lifetime risk for women to develop breast
cancer is about one in eight (American Cancer Society, 2014).

Breast cancer is now considered a heterogeneous group of diseases
that have different molecular subtypes and responses to the treatments.
Therefore, they need to be well categorized in order to achieve effective
treatments. By taking advantage of DNA microarray technology, we could
classify breast cancer gene expression profiles and cluster them into five main
molecular subtypes as shown in Figure 1. (Herschkowitz et al., 2007; Perou et
al., 2000; Prat and Perou, 2009, 2011; Vargo-Gogola and Rosen, 2007). The
five molecular subtypes are: Luminal A, Luminal B, HER2, basal-like and
claudin-low breast cancer. These subtypes can also be identified by using cell
surface receptors as biological markers including estrogen receptors (ER+/ER), progesterone receptors (PR+/PR-), and human epidermal growth factor
receptor 2 (HER2+/HER2-) (Reis-Filho and Pusztai, 2011). By categorizing
different types of breast cancer, we are able to predict the prognosis and select

5

Figure 1. The five major subtypes of breast cancer and the link to normal
human mammary epithelial hierarchy
Breast cancer can be categorized into five major subtypes by clustering their
molecular expression patterns of normal breast tissue and breast cancer. These cancer
cells may differentiate at certain stage and become one type of breast cancer. The
expression pattern of Luminal, Mesenchymal, and Basal-like is more like a
continuous spectrum instead of discrete discontinuous entities. Mammary stem cell
(MaSC) has similar expression pattern compared to Claudin-low subtype of breast
cancer. (Adapted by permission from Macmillan Publisher LtD: Nature Medicine,
Part et al., Nat Med. 2009, 15(8): 842-4, Copyright 2009).
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suitable treatments for breast cancer patients (Goldhirsch et al., 2011) as shown in
Figure 2.

7

Figure 2. Patient relapse survival and overall survival on different breast cancer
subtypes
Kaplan-Meier survival curves were plotted by using UNC337 data set. (Adapted by
permission from Elsevier: Molecular Oncology, 5(1), Prat and Perou, Deconstructing
the molecular portraits of breast cancer, 5-23, Copyright Elsevier (2011).
8

Luminal A breast cancer is the most common subtype representing
about 40% in the breast cancer population (Perou and Borresen-Dale, 2011)
and the receptor status of these tumors is ER+ and/or PR+ and HER2-.
Because of the expression of ER, hormonal therapy strategies such as
tomaxifen and aromatase inhibitors could be considered as treatment options
for patients. In clinic, luminal A breast cancer shows low proliferation, low
grade, less aggressive phenotype, and has better outcome in patient survival.

Luminal B breast cancer is ER+ and /or PR+. The HER2 status can
be either HER2+ or HER2- with high Ki67 staining. The histological grade
lymph node-positive rate is higher comparing to Luminal A (Voduc et al.,
2010). The prognosis is not so good comparing with Luminal A breast cancer,
but can use hormonal therapies as treatment options.

HER2+ breast cancer accounts for 20-25% of breast cancer cases and
is associated with poor prognosis with early and frequent recurrence (PiccartGebhart et al., 2005; Sorlie et al., 2003). Patients in this group have high level
of HER2 expression with high metastasis rate and aggressive phenotype.
Trastuzumab (Herceptin) treatment significantly improves patient survival
(Ross et al., 2003).

Basal-like breast cancer can be clinically referred to triple negative
breast cancer based on the receptor status (ER-, PR-, and HER2-) although the
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molecular expression profiles can be not exactly the same. The tumors usually have
high expression in basal epithelial markers (i.e. cytokeratins) and growth factor
receptors (i.e. EGFR) (Sorlie et al., 2003; Sotiriou et al., 2003).

Claudin-low breast cancer is recently identified by the low expression of
tight junction and cell adhesion proteins (Claudins 3, 4, 7, Occludin, and E-cadherin)
(Herschkowitz et al., 2007) with ER-, PR- HER2- phenotype. The molecular
expression pattern is similar to the stem cell stage compared to the normal mammary
development (Prat et al., 2010). The stem-cell property might contribute the
recurrence and poor prognosis in patients (Creighton et al., 2009).

There is also a group of breast cancer called normal-like breast cancer and the
gene expression pattern is very close to normal breast tissue. In fact, the normal-like
breast cancer samples for microarray studies have always contained normal breast
tissue which might explain why this group was clustered with normal breast tissue in
the gene expression profiling analysis (Prat and Perou, 2011). It needs to be further
confirmed with large scale of data. In clinic, normal-like tumors are usually small and
the patients usually have good prognosis (Carey et al., 2006; Fan et al., 2006).

In conclusion, the transcriptomic analyses allow us to understand the origin of
breast cancer and reveal potential therapeutic targets for different types of breast
cancer. Although the target therapies had been established to different types of breast
cancer, many cancer patients eventually develop resistance for their treatments. On
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the other hand, patients who were diagnosed with breast cancer may also
under multiple chronic conditions, including diabetes. Better understanding of
intervention treatments to manage breast cancer and other complications will
allow us to develop new therapeutic strategies to treat breast cancer.

1.3 Diabetes treatments, insulin levels, and anti-cancer effects
Although diabetes is a serious disease, it can be managed with proper
treatments. In the clinic, one of the primary goals to manage diabetes is to
reduce the blood glucose level in patients. Therefore, doctors may prescribe
insulin or modified insulins to diabetic patients regardless of the serum level
of insulin in the patients. More insulin will increase the uptake of glucose and
reduce the level of glucose in the blood in diabetic patients. There are other
treatment options that involved in increase insulin levels. While sylfonylureas
and glinides stimulate insulin release from the β-cells of the pancreas,
glucagon-like peptide-1 (GLP-1) receptor agonists not only stimulate insulin
secretion from the β–cells of the pancreas, but also inhibit glucagon release
from the α-cells. Besides that, DPP-4 inhibitors increase GLP-1 and glucosedependent insulinotropic polypeptide (GIP) by inhibiting the enzyme that
degrades incretin hormones. However, the increased circulating levels of
insulin is linked to a higher risk of cancer (Bowker et al., 2006; Butler, 2009;
Colhoun, 2009; Hemkens et al., 2009; Monami et al., 2009).
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There are also treatments that do not directly regulate insulin levels, such as
α–glucosidase inhibitors and amylin agonists. While α–glucosidase inhibitors block
carbohydrate digestion, amylin agonists slow down gastric emptying and inhibit
glucogon production. Surprisingly, biguanides (e.g., metformin) and
thiazolidinediones (e.g., rosiglitazone) are two common orally administered
treatments for DM2 and have showed anti-tumor effect for multiple cancer types (Ben
Sahra et al., 2008; Buzzai et al., 2007; Giovannucci et al., 2010; Girnun et al., 2007;
Hirsch et al., 2013; Monami et al., 2008), including breast cancer (Zhu et al., 2011;
Zhuang and Miskimins, 2008).

1.3.a Metformin
Metformin is recommended as a first line treatment for DM2 with high
tolerance and low side effect. Although the usage of metformin was linked to lactic
acidosis (Wiholm and Myrhed, 1993), a meta-analysis study had showed that the
incidence of lactic acidosis in the metformin and non-metformin group was 8.1 and
9.9 cases per 100,000 patient-years, respectively (Salpeter et al., 2003). Another new
study done by Bristol-Myers Squibb Company indicated that there is no lactic
acidosis in 7,227 patients who received metformin treatment (Cryer et al., 2005).
Even though the detail mechanism of metformin action is only partially
understood, the major function of metformin is to lower glucose levels and to
improve insulin sensitivity. It is believed that the high levels of organic cation
transporter 1 (OCT1) in the liver mediate hepatic metformin uptake (Shu et al., 2007).

12

Metformin improves insulin receptor sensitivity through upregulation of
insulin-receptor-substrate-2 (IRS-2) in the liver. It also increases translocation
of glucose transporter (GLUT)-1 (Gunton et al., 2003). At the same time,
metformin inhibits hepatic gluconeogenesis (Shaw et al., 2005). It is also
reported that metformin treatment increases glucose uptake in the skeletal
muscle (McIntyre et al., 1991).

Metformin is also a well-known mitochondrial complex I inhibitor
(Owen et al., 2000). Once the mitochondrial electron transport chain is
inhibited, adenosine triphosphate (ATP) production in the cell is decreased
and adenosine monophosphate (AMP)/ATP ratio is increased. The
upregulated AMP may lead to the inhibition of glucagon-induced cyclic
adenosine monophosphate (cAMP) synthesis (Miller et al., 2013) or AMPK
activation (Fryer et al., 2002). Although it is believed that metformin activated
AMPK and mediated glucose homeostasis (Zhou et al., 2001) through Liver
Kinase B1 (LKB1) (Shaw et al., 2005), a recent study indicated that
metformin inhibits hepatic gluconeogenesis through a LKB1/AMPK
independent pathway (Foretz et al., 2010).

1.3.b Rosiglitazone
Rosiglitazone is one of the thiazolidinediones (TZDs) available for
diabetic patients to control their blood glucose. TZDs are agonists of
peroxisome proliferator-activated receptor γ (PPARγ) (Lehmann et al., 1995).
13

By administrating rosiglitazone to the patients, PPARγ receptors in the nucleus are
activated in a ligand-receptor dependent fashion and increase the sensitivity of insulin
by turning on downstream gene expression that involved in glucose uptake (YkiJarvinen, 2004).

Rosiglitazone has been associated with an increased risk of heart attack, stroke
and fluid retention (Home et al., 2007; Nissen and Wolski, 2007). The U.S. Food and
Drug Administration (FDA) announced to restrict the usage on patients in 2010
(Graham and Gelperin, 2010; Graham et al., 2010). However, recent results from the
re-adjudication of Rosiglitazone Evaluated for Cardiovascular Outcomes and
Regulation of Glycemia in Diabetes (RECORD) clinical trial showed no elevated risk
of heart attack or death in patients treated with rosiglitazone comparing with other
standard treatments (Mitka, 2013). Therefore, the restriction has been removed by the
FDA on November 25th, 2013.

Rosiglitazone treatment showed decreased cancer risk in patients (Chang et al.,
2012; Monami et al., 2014; Monami et al., 2008). From previous studies,
rosiglitazone treatment induces apoptosis (Ohta et al., 2001; Zou et al., 2007), blocks
cell cycle (Han et al., 2004), promotes differentiation (Bren-Mattison et al., 2005),
inhibits angiogenesis (Keshamouni et al., 2005) and suppresses immune response
(Bren-Mattison et al., 2008). PPARγ is also one of the upstream transcriptional
regulators for PTEN (Cao et al., 2007; Lee et al., 2006; Patel et al., 2001). Increased
PTEN inhibits mTOR/AKT signaling pathway which is largely involved in
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tumorigenesis (Maehama and Dixon, 1998). Rosiglitazone treatment also
induces AMPK activation (Fryer et al., 2002; Han and Roman, 2006) and
inhibits mitochondrial oxidation independent of PPARγ signaling pathway
(Brunmair et al., 2001).

1.3.c Anti-insulin resistance treatments and HER2+ cancer
Our recent study suggested that these pharmacologic treatments for
DM2 may reduce risk, morbidity, and mortality of breast cancer with
overexpression or amplification of human epidermal growth factor receptor 2
(HER2) (He et al., 2012). Several research groups have investigated the
anticancer effect of the anti-insulin resistance treatments in HER2+ breast
cancer in vitro (Feng et al., 2011; Zhuang and Miskimins, 2008) and in vivo
(Anisimov et al., 2005a; Anisimov et al., 2005b). However, the in vitro
experiments performed in cell lines could not reflect the interaction between
cancer cells and stromal cells, and unfortunately, the in vivo xenograft
experiments were performed in nude mice or severe combined
immunodeficiency (SCID) mice that lacked an intact immune system, which
is essential for cancer progression. Moreover, neither high-fat diet-induced
nor drug-induced diabetes models can mimic diabetes development in patients.
Similarly, a transgenic diabetic model without obese conditions (Fierz et al.,
2013) also could not reflect the fact that 80% of DM2 patients are overweight
or obese. Therefore, a transgenic animal model with DM2, obesity, and an
intact immune system to evaluate the correlation between breast cancer and
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DM2 is necessary to answer the underlying questions about how anti-insulin
resistance treatments reduce cancer progression.

1.4 Gap in knowledge
Clinical studies showed that diabetes is a risk factor of breast cancer. However,
there is no animal model to address the impact of DM2 on HER2+ breast cancer.
Previous study showed that mice with homozygous leptin receptor point mutation
(Leprdb/db) did not develop oncogene-induced mammary tumors in a C57BL/6J
background (Cleary et al., 2004). However, the C57BL/6J (B6) genetic background is
resistant to carcinogenesis (DiGiovanni et al., 1993; Drinkwater and Ginsler, 1986;
Fischer et al., 1989; Rowse et al., 1998).

To clarify this question, we decided to cross MMTV-ErbB2 mice with
Leprdb/+ mice to generate a diabetic HER2+ breast cancer mouse model in a Friend
leukemia virus B (FVB) genetic background. This is the first transgenic animal in a
DM2 setting with spontaneous HER2+ tumor development and we would like to
know whether DM2 promotes breast cancer progression. Furthermore, we would like
to test that this aggressiveness caused by DM2 can be attenuated by anti-insulin
resistance treatments in a clinical relevant concentration. The data we collected are
described in the following chapters. These results may bring attention to doctors who
treat HER2+ breast cancer patients with diabetes about their choice of anti-diabetic
medications.
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CHAPTER 2. MATERIAL and METHODS

2.1 Mouse Tumor Model
MMTV-ErbB2 mice (strain name: FVB-Tg (MMTV-Erbb2)
NK1Mul/J; stock number: 005038) and Leprdb/db mice (strain name: B6.BKS
(D)-Leprdb/J; stock number: 000697) were purchased from The Jackson
Laboratory (Maine, USA). MMTV-ErbB2/Leprdb/db double-transgenic mice
were generated by crossing male MMTV-ErbB2 mice with female Leprdb/+
mice in an FVB genetic background (Figure 3). This is necessary because
MMTV-ErbB2 female mice, although fertile, are unable to lactate, and the
Leprdb/db mice were infertile. This breeding strategy resulted in the production
of all three Lepr genotypes. The offspring were maintained with their mothers
until age 21 days and then subjected to genotyping. All mouse studies were
carried out under a protocol approved by The University of Texas MD
Anderson Cancer Center Institutional Animal Care and Use Committee.

2.2 Genotyping, Weight Measurement, Oral Glucose Tolerance Tests and Insulin
Tolerance Tests
Mouse tails were snipped at weaning, and DNA was extracted from
the tail for genotyping following a standard protocol provided by The Jackson
Laboratory. The mice were weighted twice each week. The weight data were
separated and plotted based on different genotypes. Oral glucose tolerance
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tests (OGTTs) and insulin tolerance tests (ITTs) were performed as previously
described (Dezaki et al., 2004).

Figure 3. Scheme of mouse breading

MMTV-ErbB2 mice were crossed with Lepr

db/+

mice in FVB background.

Genotyping were performed, and mice carring MMTV-ErbB2 gene were collected for
further study.
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Briefly, for OGTTs, animals were fasting overnight and 1 g/kg glucose
was given to the mice via oral gavage followed by blood sampling from the
tail vein for glucose measurement. For ITTs, animals were fasting for 6 hours.
Insulin (1 U/kg) was intraperitoneally injected, and blood was collected from
the tail vein for glucose measurement. Statistical analysis was done with
GraphPad Prism for Windows.

2.3 Mammary Gland Whole-Mount Staining
Mammary gland whole-mount staining was performed following
standard procedures. Briefly, mammary glands were fixed on glass slides with
Carnoy’s solution (glacial acetic: choloroform: ethanol, 1: 3: 6) overnight at
room temperature (RT). The glands were rehydrated prior to overnight
staining in aluminum carmine (1 g carmine, 2.5 g aluminum potassium sulfate
boiled for 20 minutes in distilled water, filtered, and brought to a final volume
of 500 mL). The glands were then stored in 70% ethanol at 4ºC overnight.
Photographs were taken under a 4x power objective lens using a digital
camera mounted on a Leica MZ125 microscope (Leica Instruments, Wetzlar,
Germany). The tumor area was quantified using Image-Pro Plus software
(MediaCybernetics, Rockville, MD, USA). Statistical analysis was done with
GraphPad Prism for Windows.
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2.4 Anti-diabetic Drug Treatments
For in vivo experiments, MMTV-ErbB2/Leprdb/db mice were treated with
metformin or rosiglitazone starting at 8 weeks old. Metformin (Enzo Life Sciences,
cat# 270-432-G005) was dissolved directly in distilled water (0.5 g/kg/day).
Rosiglitazone (Cayman Chemical, cat# 71740) was dissolved in dimethyl sulfoxide as
stock solution at 100 mM and added to distilled water (1.5 mg/kg/day). The drug
treatment concentrations were within the physiologically relevant levels for diabetic
patients.

For in vitro studies, metformin was directly dissolved in cell culture medium
at desired concentrations, and 100 mM stock rosiglitazone was added into cell culture
medium at desired concentrations.

2.5 Survival Analysis
Paired mice were randomly assigned to different cohorts for survival analysis.
To assess the impact of diabetes on survival, we compared the survival time of
MMTV-ErbB2/Leprdb/db mice (n=16) with that of MMTV-ErbB2/Leprdb/db mice
(n=12). To assess the impact of anti-insulin resistance treatments on survival, we
compared MMTV-ErbB2/Leprdb/db mice treated with metformin (n=14) or
rosiglitazone (n=14) with MMTV-ErbB2/Leprdb/db mice without treatment (n=12). All
mice were monitored weekly for tumor growth and were euthanized according to
institutional protocol when tumor size reached the standard for euthanasia. Statistical
analysis was done with GraphPad Prism for Windows.
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2.6 Histology Staining and Mitosis Count
After the mice were euthanized, tumor samples were removed, washed
in phosphate buffered saline, weighted, and fixed in 10% modified formalin.
After incubation in 70% ethanol overnight, the samples were embedded in
paraffin. Paraffin-embedded sections were stained with hematoxylin and eosin
according to standard procedures, and mitotic cells were counted under 40x
high-power fields by a pathologist.

2.7 Cell Lines and Cell Culture
Mouse cell lines were isolated from MMTV-ErbB2/Leprdb/db mice and
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with high
glucose (HyClone, ref# SH30243.01) with 20% fetal bovine serum (FBS).
BT-474 and MDA-MB-361 cells were gifts from Dr. Mien-Chie Hung.
Briefly, cells were maintained in DMEM/high glucose supplemented with
10% FBS and cultured at 37 °C in 5 % CO2 conditions.

2.8 Magnetic Resonance Spectroscopic Imaging
To determine the pyruvate/lactate conversion in mice, we collaborated
with Dr. James A. Bankson in the Department of Imaging Physics at The
University of Texas MD Anderson Cancer Center, and magnetic resonance
spectroscopic imaging (MRSI) (Day et al., 2007; Golman et al., 2006) was
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performed as described below. All experiments were performed on the same mice
before and after anti-insulin resistance treatments were administered.

2.8.1 13C Polarization Process
Samples composed of 26-mg neat [1-13C] pyruvic acid containing 15 mM of
the trityl radical OX063 (GE Healthcare, Waukesha, WI) and 1.5 mM Prohance
(Bracco Diagnostics) were polarized with dynamic nuclear polarization (DNP) at 1.4
K using a Hypersense (Oxford Instruments, Abingdon, UK) polarizer. The samples
were inserted into a 3.35-Tesla vertical bore magnet and irradiated for more than 45
minutes with 94.15 GHz microwave radiation. The frozen samples were then rapidly
dissolved at 180°C in a 4 mL buffer containing 40 mM TRIS, 80 mM NaOH, and 50
mM NaCl to a final isotonic and neutral solution containing 80 mH hyperpolarized
[1-13C] pyruvate.

2.8.2 MRI Imaging Acquisition
All experiments were performed on a 7 T Biospec small animal MRI scanner
(USR70/30, Bruker Biospin MRI, MA) equipped with BGA12 gradients (120 mm
inner diameter, Gmax = 400 mT/m). A dual-tuned 1H/13C birdcage coil with 72-mm
inner diameter (1P T10334, Bruker Biospin MRI, Inc., Ettlingen, Germany) was used
for acquiring 1H reference images and performing hyperpolarized 13C dynamic
spectroscopy. Axial and coronal slices were prescribed to contain tumors in various
locations of mammary fat pads. A slice-selective pulse acquire 13C sequence (TR/TE
= 2000/2.4 ms, 2048 readout points, 4.96 kHz BW, 10° flip angle, 96 repetitions) was
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initiated prior to ~10 s the injection of 200 µL of the hyperpolarized [1-13C]
pyruvate solution was performed via tail vein.

2.8.3 Data Processing
All data were processed and analyzed using custom MATLAB (The
MathWorks, Inc., Natick, MA) scripts developed in our laboratory. For
hyperpolarized 13C experiments, data were apodized by a 15 Hz exponential
window and processed by fast Fourier transform. The signal intensity from
13

C metabolites was calculated based on the spectral area over the full width

half max, the sum of spectra over all repetitions, and the total lactate signal
normalized by the sum of total pyruvate and lactate signals.

2.9 Measurement of Oxygen Consumption Rate and Extracellular Acidification
Rate in Mouse mammary tumor cells from MMTV-ErbB2/Leprdb/db mice
To further determine the impact of anti-insulin resistance treatment on
cancer metabolism in vitro, we isolated the cancer cells from tumors of the
MMTV-ErbB2/Leprdb/db mice without any treatment and cultured the cells in a
24-well microplate (Seahorse Bioscience). The oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) were measured via a
Seahorse XF24 instrument (Seahorse Bioscience) according to the
manufacturer’s instructions. Briefly, mouse tumor cells were pretreated with
low concentration of metformin (300 µM) and then seeded in an XF24
microplate 16 hours before the experiment. Just before the Seahorse XF assay,
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the culture medium was replaced with assay medium (low-buffered DMEM
containing 25 mM D-glucose, 1 mM of sodium pyruvate, and 1 mM of L-glutamine)
and incubated for 1 hour at 37 ºC. After a baseline measurement of OCR and ECAR,
75 μl of mitochondrial respiratory chain inhibitors was sequentially injected into each
well to reach the final working 1X concentrations. After 5 minutes of mixing to
equally expose the cancer cells to the chemical inhibitors, OCR and ECAR were
measured. OCR was reported in pmol/minute/mg, and ECAR was reported in
mpH/minute/mg. Results were analyzed using Seahorse XF software. Statistical
analysis was done with GraphPad Prism for Windows.

2.10 Proliferation assay
Human HER2+ breast cancer cell lines (BT-474 and MDA-MB-361) were
split in low density in 100 mm2 dishes and cultured in DMEM/high glucose medium
with 10% FBS overnight. On the second day, cells were treated with various
concentrations of metformin in 10 ml of medium for 3 days. On the fifth day, the cells
were treated with various concentrations of metformin in an additional 10 ml of fresh
medium for another 3 days. All the supernatants and cells were collected, and cells
were counted using a Z1 Coulter Particle Counter (Beckman Coulter, Brea, CA,
USA). Triplicate samples were collected at each time point. Statistical analysis was
done with GraphPad Prism for Windows.
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2.11 Western Blot Analysis
BT-474 and MDA-MB-361 cells were treated with various
concentrations of metformin or rosiglitazone for 2 days or 6 days. Standard
Western blotting of whole-cell lysates was performed with antibodies for
PKM2, PDK1, PARP (Cell Signaling Technologies), and c-MYC (Epitomics).
β-ACTIN (Sigma) was used as a control for loading and transfer. To
determine the c-MYC proteasome-dependent degradation, BT-474 cells were
treated with metformin for 2 days, and 10 µM of MG132 was applied 6 hours
before sample collection. Cell lysates were subjected to standard Western
blotting for c-MYC. For the c-Myc ubiquitination assay, BT474 cells were
treated with MG132 for 6 hours before sample collection. Cell lysates were
immunoprecipitated with anti-ubiquitin antibody and, polyubiquitinated cMyc was immunoblotted with anti-c-MYC antibody. To determine the cMYC turnover rate, we added 500 µg/ml cycloheximide to the culture
medium, and collected samples at different time points. c-MYC density was
quantified using Image J software and plotted with GraphPad Prism for
Windows.

2.12 Quantitative Real-Time Polymerase Chain Reaction
For quantitative real-time polymerase chain reaction (qRT-PCR), total
RNA was collected from BT-474 cells using Trizol reagents (Invitrogen), and
cDNA was synthesized using an iScript cDNA synthesis kit (BioRad). qRTPCR was performed with an iQ-SYBR Green Supermix (BioRad) and an
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iCycler CFX96 RT-PCR detection system (BioRad). Primer sequences were showed
in Table 3. 18S rRNA was used for normalization. Statistical analysis was done with
GraphPad Prism for Windows.
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Table 2. Quantitative Real-Time PCR Primer List
c-MYC-Forward

5’-GCTGTAGTAATTCCAGCGAGAGACA-3

c-MYC-Reverse

5’-CTCTGCACACACGGCTCTTC-3’

PKM2-Forward

5’-CGCCCACGTGCCCCCATCATTG-3’

PKM2-Reverse

5’-CAGGGGCCTCCAGTCCAGCATTCC-3’

18S rRNA-Forward

5’-CGGCGACGACCCATTCGAAC-3’

18S rRNA-Reverse

5’-GAATCGAACCCTGATTCCCCGTC-3’
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2.13 Enzyme-linked Immunosorbent Assay
Blood samples were taken from MMTV-ErbB2/Lepr+/+ mice, MMTVErbB2/Leprdb/db mice, MMTV-ErbB2/Leprdb/db mice with metformin treatment, and
MMTV-ErbB2/Leprdb/db mice with rosiglitazone treatment. Serum samples were
collected by using BD Microtainer tubes with ethylenediaminetetraacetic acid EDTA
(REF# 365973) and were frozen at -80 °C. An enzyme-linked immunosorbent assay
(ELISA) was performed according to the manufacturer’s instructions (EMD Millipore,
rat/mouse insulin 96-well plate assay, cat# EZRMI-13K, Missouri, USA). Briefly,
mouse serum samples were thawed on ice, and 10 µl of sample was added to the plate.
Then, 80 µl of detection antibody was added to all wells. The plate was covered with
plate sealer and incubated at RT for 2 hours on an orbital microtiter plate shaker.
After the plate was washed by wash buffer, 100 µl of enzyme solution was added to
all wells, and the plate was incubated at RT for 30 minutes on the plate shaker. After
the plate was washed again with wash buffer, 100 µl of substrate solution was added
to all wells, and the plate was incubated on the shaker for 20 minutes. Then, 100 µl
stop solution was added to all wells and absorbance was measure at 450 nm and 590
nm. Statistical analysis was done with GraphPad Prism for Windows.

2.14 Multiplex Assay
Tumor samples were isolated from MMTV-ErbB2/Leprdb/db mice treated with
metformin, rosiglitazone, or control group and stored at -80 °C. Fresh tumor lysates
were prepared on assay day, and a multiplex assay was performed according to the
manufacturer’s instructions (EMD Millipore, 11-Plex Akt/mTOR Panel –
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Phosphoprotein, Cat# 48-611). Briefly, tumor lysates were diluted 1:1 with
MILLIPLEX MAP Assay Buffer 2. Bead suspension and diluted lysates were added,
and the assay plate was incubated overnight at 4 °C on a plate shaker protected from
light. On the second day after the plate was washed with wash buffer, biotinylated
reporter was added to each well, and the plate was incubated for 1 hour at RT on the
plate shaker and protected from light. After the reporter was removed via vacuum
filtration, MILLIPLEX MAP streptavidin-phycoerythrin was added to each well, and
the plate was incubated for 15 minutes at RT on the plate shaker and protected from
light. Without removing streptavidin-phycoerythrin, we added MILLIPLEX MAP
amplification buffer to each well; the plate was incubated for 15 minutes at RT on the
plate shaker and protected from light. Finally, the buffer was removed via vacuum
filtration, and the beads in each well were resuspended using MILLIPLEX MAP assay
buffer 2. The plate was read using Luminex 200, and the data were analyzed with
GraphPad Prism for Windows.

2.15 Adipokine Array Analysis
Serum samples were prepared as previously described for the ELISA. An
adipokine array assay was performed according to the manufacturer’s instructions
(R&D Systems, mouse adipokine array, Cat# ARY013). Briefly, membranes were
blocked for 1 hour on a rocking platform. Three serum samples from each group of
mice were premixed together and a detection antibody cocktail was added to serum
samples following 1 hour of incubation at RT. After the blocking solution was
removed, the sample-antibody mixtures were added to the membranes, and the
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membranes were incubated overnight at 4 °C on a rocking platform. After the
membranes were washed with wash buffer, membranes were incubated with
streptavidin-HRP solution for 30 minutes and subjected to X-ray film exposure.

2.16 Graphs and Statistical Analysis
The log-rank test was used to determine the statistical significance of survival
analysis. An unpaired t-test with Welch’s correction was performed when comparing
2 groups. One-way analysis of variance followed by Bonferroni’s multiple
comparisons test was performed when comparing 3 or more groups. All tests were
performed using GraphPad Prism version 6.0 for Windows (GraphPad Software,
LaJolla, CA, USA, www.graphpad.com). Results are expressed as means ± 95%
confidence interval (CI). P < 0.05 was considered statistically significant.
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CHAPTER 3. RESULTS

3.1 Generating MMTV-ErbB2/Leprdb/db transgenic mouse model
Previous studies had shown that diabetes inhibits mammary gland
development therefore inhibits tumorigenesis in transgenic mouse model
(Cleary et al., 2004; Zheng et al., 2011). However, the tumor resistance B6
genetic background may life span of the MMTV-drived transgenes is longer
than the Leprdb/db mice. The mice eventually died due to diabetes or obesity
before breast cancer development. To verify previous findings, we generated
our diabetic HER2+ breast cancer mouse model as shown in Figure 3.

Mice were backcrossed into an FVB genetic background, and DM2
was validated via OGTTs (Figure 4A and 4B) and ITTs (Figure 4C and 4D).
Compared with the blood glucose levels in the MMTV-ErbB2/Lepr+/+ or db/+
mice, blood glucose remained high in the MMTV-ErbB2/Leprdb/db mice,
indicating that the latter group developed diabetes. The body weight of
MMTV-ErbB2/Leprdb/db mice was significantly greater than that of their
control MMTV-ErbB2/Lepr+/+ littermates (Figure 4E).
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Figure 4. MMTV-ErbB2; Leprdb/db mice have insulin resistance and obesity
phenotype
A) Oral glucose tolerance test (OGTT) and C) Insulin tolerance test (ITT) were
performed on MMTV-ErbB2/Lepr+/+ mice (n=6) and MMTV-ErbB2/Leprdb/db mice
(n=5). Area under the curve for B) OGTT and D) ITT were plotted to show the
significance. Values are means ± 95% confident interval (CI). E) Mouse body weight
change for the MMTV-ErbB2/Lepr+/+ mice versus MMTV-ErbB2/Leprdb/db mice.
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3.1 Diabetes promotes breast cancer progression and reduces overall survival in
the MMTV-ErbB2/Leprdb/db transgenic mouse model
Next, we sought to determine the impact of diabetes on breast cancer
progression. Paired mice were dissected at the same age, and mammary glands were
isolated and subjected to whole-mount staining. The tumor volume was significantly
greater (P < 0.01) in the MMTV-ErbB2/Leprdb/db mice than in the MMTVErbB2/Lepr+/+ mice (Figure 5A and 5B). In addition, the MMTV-ErbB2/Leprdb/db
mice died at a significantly younger age than MMTV-ErbB2/Lepr+/+ mice (Figure 6A,
P = 0.0004). The median survival duration for the MMTV-ErbB2/Leprdb/db and
MMTV-ErbB2/Lepr+/+ mice was 5.9 months and 7.6 months, respectively. Tumorfree survival was also dramatically shorter in the MMTV-ErbB2/Leprdb/db than in the
MMTV-ErbB2/Lepr+/+ mice (Figure 6B, P < 0.0001). The median tumor-free survival
duration for the MMTV-ErbB2/Leprdb/db and MMTV-ErbB2/Lepr+/+ mice was 5.3
months and 6.7 months, respectively. These data indicate that DM2 group has a
poorer outcome than the non-DM2 group in the HER2+ breast cancer mouse model.
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Figure 5. DM2 promotes breast cancer progression in MMTV-ErbB2; Leprdb/db
mouse model
A) Representative mammary whole mount staining for the MMTV-ErbB2/Lepr+/+
mice versus MMTV-ErbB2/Leprdb/db mice. Tumor area was circled in yellow. LN=
lymph node. B) Quantitative analysis of A). Pictures were taken under dissection
microscope and quantified by Image-Pro software. Values are means ± 95% CI.
Mouse number: MMTV-ErbB2/Lepr+/+=13; MMTV-ErbB2/Leprdb/db=12.
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Figure 6. DM2 reduces overall survival and tumor-free survival in MMTVErbB2; Leprdb/db mouse model

A) Overall survival and B) Cumulative tumor incidence for MMTV-ErbB2/Lepr
mice (n=16) versus MMTV-ErbB2/Lepr

db/db

mice (n=12). The log-rank test was used

to determine the statistical significance of survival analysis.
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3.2 Anti-insulin resistance treatments attenuate tumor progression and improve
overall survival in HER2+ breast cancer diabetic mouse model
MMTV-ErbB2/Leprdb/db mice were assigned to one of three groups:
non-treatment control, metformin treatment, or rosiglitazone treatment. The
treatments prolonged overall survival (Figure 7A) and tumor-free survival
(Figure 7B) in the mouse model. Mammary glands were isolated from mice of
similar ages and then subjected to whole-mount staining. Whole-mount
staining showed that anti-insulin resistance treatments inhibited tumor
progression in the mammary glands (Figure 8A) and significantly reduced the
tumor size (Figure 8B, P < 0.0001). Ductal carcinoma in situ was found in the
mammary fat pad paraffin sections from mice treated with metformin,
indicating that metformin treatment postponed breast cancer progression in
MMTV-ErbB2/Leprdb/db mice (Figure 9). Histology analysis showed that
tumor samples from MMTV-ErbB2/Leprdb/db mice were poorly differentiated
with solid growth patterns, high nuclear grades, and high mitotic counts.
Compared with control samples, the anti-insulin resistance treatment groups
were moderately differentiated with glandular formation and lower mitotic
counts (Figure 10). Drug treatments extented overall survival, delayed tumor
onset, and reduced cancer aggressiveness in our diabetic HER2+ breast cancer
mouse model.
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Figure 7. Anti-insulin resistance treatments improve overall survival and tumorfree survival in MMTV-ErbB2; Leprdb/db mouse model

A) Overall survival time for MMTV-ErbB2/Lepr

db/db

mice treated with control (n=12),

metformin (n=13), and rosiglitazone (n=13). B) Cumulative tumor incidence rate for
MMTV-ErbB2/Lepr

db/db

mice in different treatment groups. The log-rank test was

used to determine the statistical significance of survival analysis.
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Figure 8. Anti-insulin resistance treatments attenuate tumor progression in
MMTV-ErbB2/Leprdb/db mice
A) Representative mammary whole mount staining for the MMTV-ErbB2/Leprdb/db
mice in different treatment groups. B) Quantitative bar graph represents of tumor size
from C). Values are means ± 95% CI. Mouse number: control=12; metformin=6;
rosiglitazone=6.
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Figure 9. Metformin treatments delays tumor progression in MMTVErbB2/Leprdb/db mice
A) Mammary fat pads were collected from metformin treatment mice and H&E
staining was performed on paraffin sections. A low power view (20X) shows two
microscopic foci of dauctal carcinoma in situ (DCIS). B) and C) Enlarged view of
two foci of DCIS, which shows enlarged ducts with solid proliferation of
polymorphic tumor cells with high nuclear and cytoplasmic ratio. Arrow points
mitotic figure.
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Figure 10. Anti-insulin resistant treatments repress cancer progression in
MMTV-ErbB2/Leprdb/db mice.
Tumor samples were harvested from different treatment groups and H&E staining
was performed on paraffin sections. Pictures were taken under 40X and pathology
analysis was done by pathologist. Arrow: mitosis. Scale bar: 100 μm.
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3.3 Anti-insulin resistance treatments reduce the cancer metabolism in vivo
To determine whether anti-insulin resistance treatments change the dynamics
of the metabolic processes in MMTV-ErbB2/Leprdb/db mice, we performed MRSI to
monitor the dynamic flux of pyruvate into lactate, which is the end product of aerobic
glycolysis and an important marker for cancer metabolism. MRI was performed
before the substrate [1-13C] pyruvate injection, and the tumor area was located
(Figure 11). By taking advantage of hyperpolarized technology, we injected the
substrate [1-13C] pyruvate into MMTB-ErbB2/Leprdb/db mice and traced the [1-13C]
signal to lactate in vivo (Figure 12A and 12B). Metformin treatment for 2 weeks
caused about an 80% reduction in pyruvate/lactate conversion (Figure 12A and 12C),
and 2 days of rosiglitazone treatment showed about a 50% reduction (Figure 12B and
12C). These data indicate that anti-insulin resistance treatments reduce
pyruvate/lactate conversion and alter cancer metabolism in vivo.
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Figure 11. MRI image of tumor localization in a MMTV-ErbB2/Leprdb/db mouse
Representative T2-weighted magnetic resonance imaging (MRI) for localization of
the tumor in a living MMTV-ErbB2/Leprdb/db mouse before hyperpolarized 13Cpyruvate injection.
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Figure 12. Anti-insulin resistant treatments reduce cancer metabolism in vivo
and in vitro
A) Magnetic resonance spectroscopic imaging (MRSI) was performed on MMTVErbB2/Leprdb/db mice. Chemical shift after hyperpolarized 13C-pyruvate was injected
into MMTV-ErbB2/Leprdb/db mice before (left) or after (right) metformin treatment
and B) rosiglitazone treatment. C) Quantitative bar graph represents the
lactate/pyruvate conversion in tumor from A) and B)
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3.4 Metformin treatment reduces mitochondrial respiration capacity and
glycolysis in vitro
To further evaluate the impact of metformin treatment on cancer metabolism,
we isolated cancer cells from the primary tumors of MMTB-ErbB2/Leprdb/db mice and
seeded them into a Seahorse microplate. OCR and ECAR were measured using the
Seahorse instrument. OCR was significantly lower in cells treated with 300 µM
metformin than in non-treated cells (Figure 13A), indicating that mitochondrial
respiration capacity was altered. Decreased ECAR also indicated that lactate
production was attenuated, which confirms that glycolysis was reduced by metformin
treatment (Figure 13B), as we observed in the MRSI experiment in vivo. These data
suggest that mitochondrial respiration and both anaerobic and aerobic glycolysis were
reduced upon metformin treatment. Statistical analysis of the area under the curve for
OCR and ECAR revealed a significant reduction after metformin treatment (Figure
13C).
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Figure 13. Metformin treatment reduces oxygen consumption (OCR) and extra
cellular acidification rate (ECAR) in vitro
A) OCR and B) ECAR were measured by Seahorse analyzer. Tumor cells were
harvested from MMTV-ErbB2/Leprdb/db mice without any treatment and seeded into
96-well plate for Seahorse analysis. Values are means ± standard deviation. C)
Quantitative analysis of OCAR and ECAR from A) and B). Values are means ± 95%
CI.

47

3.5 Metformin treatment inhibits proliferation, induces apoptosis, and
suppresses cancer metabolism in human HER2+ breast cancer cell lines
To determine whether metformin treatment also represses cancer progression
and cancer metabolism in human HER2+ breast cancer cells, we conducted the
following experiments using BT-474 and MDA-MB-361 cells. We first split the cells
at low density in 100 mm2 dishes and treated the cells with metformin at various
concentrations for 6 days. To ensure the minimum loss of dead or detached cells, we
applied an additional 10 ml of medium and metformin without removing any culture
medium. All supernatant and cells were collected, and the cells were quantified via a
Z1 Coulter Particle Counter. In fact, metformin treatment efficiently inhibited cell
proliferation (one-way analysis of variance, P<0.001, Figure 14A and 14B) started
from 500 µM and induced apoptosis at 2000 µM (Figure 14C).

From the previous experiments (Figure 12 and 13), we learned that antiinsulin resistance treatments reduced cancer metabolism in vivo and in vitro. We
therefore sought to determine the target of metformin treatment in human HER2+
breast cancer cell lines. c-MYC is a major player in cancer metabolism by controlling
many enzymes in the glycolysis pathway at the transcriptional level. We sought to
determine whether metformin treatment is involved in regulating c-MYC expression.
Indeed, Western blotting showed that c-MYC expression was suppressed by
metformin treatment (Figure 14C).
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Figure 14. Metformin treatment inhibits cell proliferation, increases apoptosis,
and suppresses key metabolism regulators in Her2+ human breast cancer cell
lines.
A) BT-474 and B) MDA-MB-361 cell proliferation after 6 day metformin treatment
at various concentrations. C) Western blot analysis of key metabolic protein
expression and PARP cleavage after 6 days metformin treatment.
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In addition, PKM2, the key step enzyme for pyruvate/lactate conversion also
controlled by c-MYC, was downregulated by metformin treatment (Figure 14C).
These data provide the link between the reductions in c-MYC, PKM2, and lactate
production that we observed in vivo (Figure 12) and in vitro (Figure 13). We also
performed qRT-PCR in BT-474 cells to determine the mRNA expression level of cMYC and its downstream targets. Our data indicated that both c-MYC and PKM2
were downregulated at the transcriptional level in the presence of 500 µM metformin
treatment (Figure 15A). After 2 days of metformin treatment, the c-MYC protein
level was restored to a level comparable to that of the control in the presence of
MG132, indicating that metformin treatment has a secondary mechanism of
proteasome-dependent degradation (Figure 15B). A band at high molecular weight
was found in the stacking gel of the ubiquitination assay, suggesting that c-MYC was
highly ubiquitinated and degraded upon 2 days of metformin treatment (Figure 4F).
The c-MYC protein turnover rate was also greater than that of the control (Figure 4G).
Collectively, our results show that metformin treatment at clinical relevant
concentrations regulates cell metabolism by downregulating c-MYC at both
transcriptional and post-translational levels.
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Figure 15. Metformin treatment suppresses PKM2 gene expression through
inhibiting c-MYC expression and promoting c-MYC degradation in Her2+
human breast cancer cell lines
A) Real-Time PCR analysis of c-MYC (left) and PKM2 (right) mRNA expression in
BT-474 cells after 2 days metformin treatment at various concentration. B) BT-474
cells were pretreated with metformin for 2 days and cell lysates were collected after 6
hours MG132 treatment. c-MYC protein level were shown in western blot. C) BT474
cells were treated with MG132 for 6 hours before harvesting. Cell lysates were
immunoprecipitated with anti-ubiquitin antibody and polyubiquitinated c-Myc was
immunoblotted with anti-c-MYC antibody. Arrow indicated highly ubiquitinated cMYC at stacking gel. D) BT-474 cells were pretreated with metformin for 2 days and
cell lysates were collected after cycloheximide (CHX) treatment at various time
points. Western bolt represented the c-MYC protein level. E) c-MYC protein
turnover. Quantitative analysis for c-MYC protein from the upper panel. Density was
set as 100% at zero time point in each group.
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3.6 Anti-insulin resistance treatments reduce systemic insulin level, suppress
mTOR/AKT signaling in tumor, and regulate adipokine secretion profiles
From our aforementioned results, we learned that metformin treatment
can efficiently suppress mitochondrial respiration, lactate production,
proliferation and c-MYC mRNA expression in cancer cells. Next, we sought
to evaluate the systemic impact of anti-insulin resistance treatments on our
diabetic HER2+ breast cancer mouse model. Since metformin is the first-line
treatment for DM2, we expected metformin treatment to improve insulin
resistance in MMTV-ErbB2/Leprdb/db mice (Figure 16). To further evaluate the
systemic effect of anti-diabetic treatments in vivo, we performed a rat/mouse
insulin ELISA assay. The level of insulin was 15-fold higher in the MMTVErbB2/Leprdb/db mice than in the MMTV-ErbB2/Lepr+/+ mice (P<0.001), and
dramatically decreasing in metformin and rosiglitazone treatment groups
(P<0.01, Figure 17). This microenvironment change limited the insulin supply
to the cancer cells and suppressed the mTOR/AKT signaling pathway in
mouse tumors as shown by p-AKT-S473 and p-RPS6-S235/S236 (Figure 18).

DM2 is a severe metabolic disease and often comes with increased
body weight and adipose tissue. Therefore, we sought to assess the adipokine
profile changes in MMTV-ErbB2/Leprdb/db mice (Figure 19A), and more
importantly, assess the profile upon anti-insulin resistance treatments (Figure
19B). Interestingly, we found that drug treatments reversed the impact of
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DM2 on the expression level of Adiponectin, Fibroblast growth factor 1 (FGF1),
Chemokine (C-C motif) ligand 2
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Figure 16. Metformin treatment improved type 2 diabetes in MMTVErbB2/Leprdb/db breast cancer mouse model
A) OGTT and B) ITT were performed on MMTV-ErbB2/Leprdb/db mice (n=4) before
and after 2 weeks metformin treatment on the same mice. Area under the curve for C)
OGTT and D) ITT was analyzed. Paired t-test was performed to show the significant
difference. Values are means ± 95% CI.
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Figure 17. DM2 condition increases insulin levels and anti-insulin resistance
treatments significantly reduce insulin levels in MMTV-ErbB2/Leprdb/db breast
cancer mouse model
ELISA analysis for the serum insulin level was performed from different groups of
mice. WT: MMTV-ErbB2/Lepr+/+ mice=10; DB: MMTV-ErbB2/Leprdb/db
mice/control=12; DB/Met: MMTV-ErbB2/Leprdb/db mice/metformin treatment=10;
DB/Rosi: MMTV-ErbB2/Leprdb/db mice/rosiglitazone=16. Values are means ± 95% CI.
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Figure 18. Multiplex analysis for mTOR/Akt signaling pathway
Tumors were harvested from MMTV-ErbB2/Leprdb/db mice treated with control
(n=24), metformin (n=6), and rosiglitazone (n=6).
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Figure 19. Adipokine expression profile in MMTV-ErbB2/Leprdb/db mice

A) Serum adipokine levels in MMTV-ErbB2/Lepr
ErbB2/Lepr

+/+

db/db

mice comparing with MMTV-

mice. Serum samples from 3 mice of each group were mixed before

incubating with adipokine array. B) Adipokine expression profile for MMTVErbB2/Lepr

db/db

mice treated with control, metformin, and rosiglitazone.
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(MCP1) and receptor of advance glycosylation end products (RAGE). These
adipokines may associate with anti-insulin resistance treatments and contribute to the
beneficial impact on HER2+ breast cancer progression.
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CHAPTER 4. DISSCUSSION

Our findings suggest that DM2 promotes the progression of HER2+ breast
cancer, and this aggressiveness is attenuated by anti-insulin resistance treatments. We
also successfully established a transgenic animal model and confirmed that the
survival duration of mice with DM2 and HER2+ breast cancer was shorter than that of
control mice. Furthermore, by administrating anti-insulin resistance treatments to the
diabetic HER2+ breast cancer model, we demonstrated that metformin and
rosiglitazone treatments significantly prolong overall survival and alter the metabolic
status. All these results indicate the potential application of anti-insulin resistance
treatments in HER2+ breast cancer patients with DM2.

4.1 A successful DM2 HER2+ breast cancer transgenic mouse model
Leprdb/db mice were discovered more than 40 years ago as an animal model in
DM2 research (Belke and Severson, 2012; Hummel et al., 1966). Previous studies
indicated that the Leprdb/db mouse model has deficient mammary gland development
on a C57BL/6 genetic background. Cleary et al. (Cleary et al., 2004) and Zheng et al.
(Zheng et al., 2011) also tried to cross MMTV-TGF-α mice or MMTV-Wnt-1 mice
with Leprdb/+ mice and maintain the mice on a C57BL/6 genetic background. They
claimed that the leptin receptor deficiency suppressed the development of mammary
tumors. However, the life expectancy of the MMTV-TGF-α mice or MMTV-Wnt-1
mice is longer than that of Leprdb/db mice, and the C57BL/6 genetic background is
actually resistant to tumor progression in mouse models. In our study, we crossed our
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transgenic mouse model in a tumor-prone FVB genetic background instead of
a tumor-resistant C57BL/6 genetic background and found that DM2 promotes
HER2+ breast cancer progression. To our knowledge, we are the first group to
successfully generate hyperinsulinemic, hyperglycemic, and obese MMTVErbB2/Leprdb/db mice. Therefore, we could use this animal model to assess the
therapeutic effect of anti-insulin resistance agents.

4.2 Demonstrating the anti-cancer effect of anti-insulin resistance treatments by
using clinical relevant concentration
Metformin is the most frequently prescribed anti-insulin resistance
drug for DM2 patients, and many studies have shown that both metformin and
rosiglitazone have anticancer activity. Studies showed that treatment with
metformin and/or rosiglitazone inhibited cancer cell proliferation (Feng et al.,
2011; Zhuang and Miskimins, 2008), induced cell apoptosis (Feng et al.,
2011), selectively reduced cancer stem cell populations in vitro (Hirsch et al.,
2013; Hirsch et al., 2009), and attenuated cancer cell growth in vivo
(Anisimov et al., 2005a; Anisimov et al., 2005b; Fierz et al., 2013). However,
none of these studies revealed alterations in breast cancer metabolism in vivo,
and the majority studies of anti-insulin resistance treatments used either a
high-fat diet or drugs to induce diabetes or the engraftment of tumor cells in
the mice, which does not represent the true circumstances of cancer
progression in the presence of DM2 in a transgenic setting. Moreover, the
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majority of the studies were conducted by using metformin and/or rosiglitazone at
concentrations that were not clinically relevant.

Other studies did not test these agents in an obese DM2 mouse model.
Anisimov et al. showed the impact of metformin on tumor progression and survival in
non-diabetic MMTV-ErbB2 mice (Anisimov et al., 2005a). Similarly, Fierz et al.
established the effects of anti-diabetic drugs in a nonobese DM2 mouse model (Fierz
et al., 2013). We sought to assess the effects of anti-insulin resistance treatments in
the setting of HER2+ breast cancer, DM2, and obesity. Therefore, we treated our
MMTV-ErbB2/Leprdb/db mice with metformin or rosiglitazone at a clinical relevant
concentration before palpable tumor formation and observed that tumor progression
was significantly reduced and survival time was prolonged. In addition, the drugs did
not inhibit tumor progression once the tumor had been established, indicating that the
anti-diabetic drugs work better as cancer prevention agents (data not shown).

4.3 Real-time observation of anti-insulin resistance treatments alter breast
cancer metabolism by directly inhibiting oxidative phosphorylation and
glycolysis in vitro and in vivo
By assessing our MMTV-ErbB2/Leprdb/db mice with MRSI, we found that
metformin or rosiglitazone treatments reduced cancer metabolism in the living mice.
For this particular method, we monitored the glycolysis real-time in vivo.
Interestingly, the rate at which 13C-pyruvate was converted to 13C-lactate was reduced
significantly after 2 days of rosiglitazone treatment (Figure 12B), but not after 2 days
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of metformin treatment (data not shown). The reduction in pyruvate/lactate
conversion was found in the group treated with metformin for 2 weeks (Figure
12A), indicating that the physiologically relevant concentration of oral
metformin may affect cancer metabolism only in a long-term treatment
regimen. These results suggest that metformin and rosiglitazone regulate
cancer metabolism via different mechanisms that need to be investigated.

Warburg effect is an important factor in cell metabolism (Vander
Heiden et al., 2009; Warburg, 1956) and one of the hallmarks of cancer
(Hanahan and Weinberg, 2011; Yeung et al., 2008). Regardless of whether
oxygen is present, cancer cells tend to undergo aerobic glycolysis and convert
most glucose to lactate instead of moving into TCA cycle. To confirm our
observation in vivo, we isolated cancer cells from the primary tumor sites of
MMTV-ErbB2/Leprdb/db mice and monitored the impact of metformin
treatment directly on cancer cells. As a well-known mitochondrial complex I
inhibitor (Owen et al., 2000), metformin at a clinically relevant concentration
efficiently suppressed oxygen consumption, indicating that the mitochondrial
respiratory chain reaction was repressed (Figure 13A). Although a previous
study indicated that glycolysis increases when mitochondrial complex I is
inhibited owing to the glycolysis flux (Brunmair et al., 2004), we observed
that lactate production was decreased upon treatment with 300 µM metformin
(Figure 13B), which is consistent with the MRSI finding. This result
demonstrated that metformin may also affect multiple key components in the
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glycolysis pathway, of which c-MYC is a primary regulator (Miller et al., 2012).

4.4 Metformin treatment inhibits c-MYC mRNA expression and induces c-MYC
proteasome degradation
To expend our study closer to human, we selected two human HER2+ breast
cancer cell lines for our in vitro experiments. The proliferation of both BT-474 and
MDA-MB-361 cells was inhibited at a clinically relevant concentration of metformin
treatment (Figure 14A and 14B). However, metformin treatment induced apoptosis at
a higher dose that was not a clinically relevant concentration (Figure 14C). c-MYC
protein level was indeed decreasing upon metformin treatment. Additionally, the cMYC downstream target PKM2, which is important for switching the metabolism to
aerobic glycolysis (Christofk et al., 2008) was also repressed (Figure 14C and 15A).
These findings may explain why there was no increase of lactate production when
oxidative phosphorylation was inhibited. At the end, the glycolysis flux may have
been blocked, and the metabolites may have been converted to phosphoenolpyruvate
(PEP), 2-phosphoglycerate and 3-phosphoglycerate (2- and 3-PGA) as previous
described (Owen et al., 2000). These intermediate metabolites are precursors for the
pentose phosphate pathway (PPP) to synthesis nucleotides as building blocks for
cancer cells. These accumulated intermediated metabolites also explain why
metformin treatment can only postpone cancer progression but cannot eradicate it.

We next sought to determine the extent to which c-MYC is reduced at the
transcriptional and/or post-translational level. Upon 500μM metformin treatment,
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there was a significant difference at the c-MYC mRNA level (Figure 15A),
suggesting that metformin may modulate c-MYC in a DICER-microRNA-33c-MYC cascade according to previous findings (Blandino et al., 2012). In
addition, c-MYC protein was restored to a comparable level in the presence of
MG132, suggesting that metformin treatment was involved in c-MYC
degradation (Figure 15B). For the ubiquitination assay, the endogenous cMYC ubiquitination was first detected via immunoprecipitation with antiubiquitin antibody and then immunoblotted with anti-c-MYC antibody in BT474 cells. The stacking gel was intentionally preserved, and Western blotting
was performed for the whole gel. A highly ubiquitinated c-MYC was found in
the stacking gel, and metformin treatment induced ubiquitination starting at
500 µM (Figure 15C). Although high concentrations of metformin treatment
did not cause c-MYC ubiquitination in a dose-dependent manner in BT-474
cells, the clinically irrelevant concentrations may already disrupt and affect
normal protein production in the cells. The c-MYC turnover rate was faster in
the presence of 500 µM metformin (Figure 15D and E), supporting the notion
that metformin treatment promotes c-MYC protein degradation.

4.5 Systematic effect of anti-insulin resistance treatments on breast cancer and
microenvironment
Besides the impact of anti-insulin resistance treatments in cancer, we
evaluated the systemic effects of the anti-insulin resistance treatments and the
potential crosstalk between cancer cells and the microenvironment in our
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diabetic HER2+ mouse model. The serum insulin level (Figure 17) was reduced, and
insulin resistance was improved in MMTV-ErbB2/Leprdb/db mice (Figure S3) after
anti-insulin resistance treatments. Although the downstream targets of insulin
receptor signaling pathway and HER2 signaling pathway are overlap, anti-insulin
resistance treatments prevented further stimulation from insulin and attenuated the
mTOR/AKT signaling pathway (Figure 18), thereby gradually preventing cancer
progression. In addition, by analyzing the adipokine profile, we identified the
adipokines that were up-regulated under diabetic conditions (Figure 19A) and found
adiponectin, FGF-1, MCP-1, and RAGE were significantly down-regulated by antiinsulin resistance treatments (Figure 19B). These four adipokines may serve as anticancer regulators in HER2+ breast cancer progression. This finding supports the idea
that anti-insulin resistance treatments at clinically relevant concentration not only
altered cancer cell metabolism but also rendered the microenvironment unfavorable to
tumor progression in our diabetic HER2+ breast cancer mouse model.

In conclusion, we established a new animal model to assess the impact of
DM2 on breast cancer progression and showed that anti-insulin resistance treatments
may delay tumor onset and retard cancer progression in MMTV-ErbB2/Leprdb/db mice.
The treatments not only stopped proliferation and altered metabolism in cancer cells
but also changed the microenvironment through systemic regulation of insulin levels
and adipokine expression. To take bench research to the bedside, these results suggest
that anti-diabetic drugs may be used as cancer prevention agents for diabetic patients
who have increased risk of HER2+ breast cancer.
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4.6 Future direction
It had been shown that metformin and rosiglitazone react through
distinct pathway (Fryer et al., 2002). Our data 13C-pyruvate data showed that
metformin required longer treatment (2 weeks) to be able to reduced
lactate/pyruvate conversion, while rosiglitazone only needed 2 days to achieve
the inhibition. In addition, metformin treatment also inhibited alanine to
pyruvate conversion (5.99%) while rosiglitazone actually increased it
(175.68%) (data not shown). These data suggest that metformin not only
inhibits glycolysis, it may also inhibit amino acids synthesis as building
blocks for cancer cells. If metformin treatment is able to inhibit oxidative
phosphorylation, aerobic glycolysis, and amino acid synthesis at the same
time, where the glucose metabolites go? Previous study showed that an
intermediate of the de novo purine nucleotide synthesis pathway, SAICAR
(succinylaminoimidazolecarboxamide ribose-5’-phosphate), was involved in
regulating PKM2 and was able to promote cancer cell survival (Keller et al.,
2012). To find the metabolites that potentially keep cancer cell survive may be
the key to cure breast cancer.

In our study, we found that metformin treatment induces c-MYC
proteasome degradation. However, what mechanism and which E3 ligase is
involved needs to be clarified. I previously identified that Pin1
phosphorylation at serine 71 is necessary to form the 14-3-3σ-pin1-MYC
complex and mediated c-MYC degradation. It will be interesting to see
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whether metformin treatment increases Pin1 or 14-3-3σ protein levels or stimulates
PIN1 S71 phosphorylation.

We identified FGF1, MCP1 and RAGE could be the potential anti-cancer
adipokines as therapeutic options for drug development. For example, MCP1 is a
monocyte chemoattractant protein which may involve in the monocyte infiltration as
cancer progress. Since metformin and rosiglitazone can inhibit the inflammatory
response (Hirsch et al., 2013; Yki-Jarvinen, 2004), it is very interesting to know how
anti-insulin resistance treatments can inhibit MCP1 secretion. I previously tried to
link the reduction of MCP1 by using cancer cells as the model but failed. However,
the MCP1 reduction could be the effect of drug treatments on microenvironment.
Therefore, the direction should focus on adipocytes or stromal cells instead of cancer
cells. In conclusion, solving these underlying questions may lead us to find new
therapeutic targets for breast cancer.
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